Xenon Pharmaceuticals (XENE) PreEpilipsy Data NDR Hints at 70% Upside Near Term - Jefferies
Tweet Send to a Friend
Jefferies analyst Andrew Tsai reiterated a Buy rating and $28.00 price target on Xenon Pharmaceuticals (NASDAQ: XENE) after hosting 15+ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
